/PRNewswire/ Syndivia, a leading biotechnology company at the forefront of innovative DAR1 ADCs (antibody-drug conjugates with a drug-to-antibody ratio of.
/PRNewswire/ The "ADC Contract Manufacturing Market by Phase of Development, Scale of Operation, Type of Component Manufacturing, Target Indications, Type.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The report offers a comprehensive study of the current scenario and future potential of the ADC contract manufacturing market. The study features an in-depth analysis, highlighting the capabilities of contract services providers engaged in this domain.
Overview
Since the success of ADCETRIS (approved in 2011), antibody drug conjugates (ADCs) are now considered a versatile therapeutic tool and have been accepted into the contemporary portfolio of mainstream healthcare solutions. Over time, clinical researchers have been able to further their understanding of the intricacies of ADC design and have also improved the development process of these complex pharmacological interventions.
ADC Contract Manufacturing Market, 2020-2030
New York, Dec. 11, 2020 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report ADC Contract Manufacturing Market, 2020-2030 - https://www.reportlinker.com/p03290025/?utm source=GNW Over time, clinical researchers have been able to further their understanding of the intricacies of ADC design and have also improved the development process of these complex pharmacological interventions. Some of the recently approved ADC therapeutics include BLENREP® (2020), TRODELVYTM (2020), PadcevTM (2019) and POLIVY® (2019). In addition, there are close to 250 unique ADC product candidates under development. Several big pharma players, including AstraZeneca, GlaxoSmithKline, Pfizer, Roche and Takeda, have also acquired stake in this market. Moreover, the fact that companies involved in the development of ADCs, have received over USD 5 billion in capital investments (since 2011), attests to the therapeutic potential and growing p